Skip to main content
Bellicum Pharmaceuticals, Inc.Portfolio

Bellicum Pharmaceuticals: Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO

By December 14, 2018March 9th, 2021No Comments

Bellicum Pharmaceuticals, Inc.
Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO
Rimiducid-activated GoCAR-T® resulted in significant expansion and persistence of T cells
Initial evidence of biologic activity and stable disease observed in some patients with single rimiducid dose
BPX-601 was well-tolerated with no CRS or neurotoxicity reported in initial cell-dose escalation
Company to add additional tumor types in Part 2 of study, incorporating standard lymphodepletion and repeat rimiducid dosing
December 14, 2018